PDE10A and ovarian carcinoma: PDE10A DNA gain and amplification was observed in 13.7% of the TCGA ovarian cancer patients, and this subset had significantly decreased disease-free survival when compared to the remainder of patients with heterozygous/homozygous loss or unaltered PDE10A copy number (11 vs. 18 months; p = 0.0417) (Fig. S1C-D).